The goal of this collaboration is to develop a test that will enable physicians to distinguish between patients with high and low risk of recurrence to optimize treatment regimens.
Amir Avniel, president and CEO of Rosetta Genomics, said: “We believe that the experience we have in working with microRNA biomarkers, combined with MD Anderson’s extensive experience in lung cancer research, makes this a strong collaboration which may have a significant impact on the way lung cancer patients are diagnosed and treated.”